UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
Comparator Study of 68Ga-DOTATOC PET/CT with Octreoscan + high-resolution, contrast-enhanced CT for diagnosis and staging in neuroendocrine tumors and other somatostatin receptor positive tumors

Participants in this research study have been diagnosed with a tumor such as carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells with special proteins called somatostatin receptors.

The purpose of this research study is to see if the tumors can be identified using a special procedure called a positron emission tomography (PET) scan and see if it is as effective as having an Octreoscan and a diagnostic CT. Participants will have an injection with a radioactive drug called 68Gallium-DOTA-tyr3-Octreotide (68Ga-DOTATOC) that binds to tumor cells that have somatostatin receptors and then have a PET scan. A "low dose" computed tomography (CT) scan will then be done on the same scanner. 68Ga-DOTATOC is considered investigational, which means that it has not yet been approved by the U.S. Food and Drug Administration (FDA). The FDA has granted permission to conduct this study under an investigator's new drug (IND) application.

About 112 people will take part in this study conducted by investigators at the University of Iowa.

Start Date
April 1, 2013
End Date
January 1, 2015
Gender Preference
Age Group
2 - 99 years
Principal Investigator
M. Sue O'Dorisio, MD
Contact Info

Mary Schall, 319-356-3516

brain tumor ; cancer ; carcinoid tumor ; IRB#201212736 ; neuroblastoma ; neuroendocrine tumor ; o ; pediatric ; phase 2 ; phase II ; positron emission tomography (PET) scan ; somatostatin receptors ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.